Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in plasma powerhouse

Grifols S.A. stock jumped sharply on the Madrid Stock Exchange following the board's approval on March 24, 2026, to explore a potential US initial public offering for a minority stake in its US biopharma business. This unit, the largest plasma collector in America with nearly 300 donation centers across 40 states, drives over half of the group's revenues and positions Grifols as a vertically integrated leader in plasma-derived medicines. For US investors, the development signals a rare opportunity to gain direct exposure to a powerhouse operation that sidesteps foreign supply risks, especially as global demand for immunoglobulins surges post-pandemic.

As of: 26.03.2026

Dr. Elena Vargas, Senior Biotech Analyst: Grifols' bold step toward listing its US plasma operations separately unlocks hidden value in a market where self-sufficiency is the ultimate competitive edge, particularly for American investors seeking pure-play biotech resilience.

Board Approval Ignites Market Rally on Madrid Exchange

The Grifols S.A. class A shares, ticker GRF under ISIN ES0171996087, surged in response to the announcement, reflecting investor enthusiasm for separating the high-margin US asset. This biopharma subsidiary handles plasma collection, fractionation, and manufacturing entirely within the United States, including key facilities in California and North Carolina. The move addresses longstanding concerns over the group's debt pile by potentially raising capital through a minority stake sale while retaining majority control at the parent level.

Grifols emphasized that the IPO evaluation reinforces its vision of creating the first fully self-sufficient plasma player in the US, independent of foreign plasma, manufacturing, or supply chains. Plasma-derived products account for 85.2% of net sales, with the United States and Canada contributing 56.7% of total revenues. This geographic and product concentration underscores why the market reacted swiftly, as investors price in deleveraging proceeds funding growth without diluting core operations.

The announcement came just weeks after Grifols projected over 25% EBITDA growth for 2026, following a more than doubling of 2025 profits. Such financial momentum amplifies the appeal, positioning the potential US listing as a catalyst for further multiple expansion on the parent stock listed on the BME as part of the IBEX-35 index.

US Biopharma Unit: A Vertically Integrated Powerhouse

At the heart of the IPO plan lies Grifols' US biopharma business, employing over 14,000 people and operating nearly 300 plasma donation centers spread across 40 states. This network feeds into advanced manufacturing sites that produce critical therapies like Flebogamma for immunodeficiency and Prolastin for alpha-1 antitrypsin deficiency. Vertical integration from collection to final product distribution creates a moat against supply disruptions that have plagued peers during global shortages.

Unlike competitors such as CSL Behring or Takeda, which depend on multinational plasma flows, Grifols' US operations achieve full self-sufficiency. This setup mitigates FDA import risks, logistics vulnerabilities, and geopolitical tensions over biological materials. In a sector where plasma supply remains the biggest bottleneck—global collections have struggled to match rising therapy demand—these assets command premium valuations.

Grifols, founded in 1909 in Barcelona, has grown into a global leader with 25,258 employees across more than 30 countries. Yet its US footprint dominates, highlighting why spinning out a stake could crystallize value currently obscured within the conglomerate structure that also includes diagnostics (8.9% of sales) and hospital products (3%).

Strategic Debt Reduction and Growth Acceleration

Proceeds from the potential IPO would primarily target Grifols' substantial debt load, a persistent overhang that has pressured the stock in recent years. By listing a minority stake, the company aims to deleverage without losing control, freeing up capital for expansion in plasma collection and diagnostic businesses outside the US. This disciplined approach aligns with recent guidance of robust EBITDA expansion, signaling confidence in underlying operations.

The plasma industry faces chronic supply constraints, with demand for therapies treating rare diseases and immune disorders growing at double-digit rates. Grifols' US self-sufficiency positions it to capture more market share, potentially boosting utilization rates at its centers and improving fractionation yields. Investors view this as a pathway to margin expansion, especially as pricing power strengthens in a supply-tight environment.

Parent company Grifols S.A. would refocus on its remaining segments, potentially enhancing appeal within the IBEX-35. Class B shares and existing ADRs (ticker GRFS) already provide US access, but a dedicated IPO could attract institutional buyers seeking pure exposure to plasma economics.

Why US Investors Should Watch Closely Now

For American investors, the potential IPO represents a direct entry into the world's premier plasma collection network, bypassing the ADR premium and foreign listing discounts. With over 14,000 US jobs and facilities deeply embedded in the domestic healthcare ecosystem, the unit embodies stability amid sector volatility. As hyperscalers of biotech, US institutions could anchor the offering, driving liquidity and valuation uplift.

Plasma therapies enjoy favorable reimbursement dynamics in the US, supported by orphan drug status for many indications. Grifols' scale enables economies that smaller players can't match, from donor recruitment to regulatory compliance. This comes at a time when biotech valuations reward resilient cash flows over speculative pipelines, making the US biopharma pure-play particularly attractive.

Current ADR holders might benefit from arbitrage opportunities as the new listing clarifies asset values. Broader US interest stems from the sector's defensive qualities—recession-resistant demand tied to chronic conditions—offering diversification beyond high-growth tech or cyclicals.

Competitive Moat in a Supply-Constrained Market

Grifols differentiates through its end-to-end control, a rarity in plasma where collection volumes dictate profitability. Nearly 300 centers ensure steady supply, buffering against donor fluctuations that hit fragmented competitors. Products like immunoglobulins command high margins due to limited substitutes, with US self-sufficiency shielding against tariff or regulatory hurdles on imports.

Recent industry dynamics favor incumbents: post-COVID collections rebounded, but demand outpaces supply, supporting price hikes. Grifols' manufacturing prowess—advanced fractionation yielding more therapies per liter—amplifies returns. The IPO could fund capacity additions, solidifying dominance as therapies expand into neurology and beyond.

Geographic revenue split—56.7% from US and Canada—highlights dependency, but also opportunity. A US listing elevates visibility among stateside funds, potentially narrowing the valuation gap to pure-plays like Octapharma or smaller fractionators.

Risks and Open Questions Ahead

While promising, the IPO path carries execution risks: market timing amid biotech volatility could pressure pricing, and regulatory scrutiny on plasma operations remains intense. Debt reduction assumes favorable terms, but high interest environments might limit upside. Retaining majority control mitigates some concerns, yet minority investors may demand governance changes.

Plasma supply vulnerability persists—donor regulations or pandemics could disrupt collections. Competition intensifies as new entrants eye the market, though Grifols' scale provides defense. Valuation disconnect between parent and spun unit poses arbitrage risks if Madrid lags US enthusiasm.

Broader uncertainties include forex exposure for euro-listed shares and EU regulatory shifts affecting non-US ops. Investors must weigh these against the transformative potential, monitoring progress toward filing.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.